Schizophrenia, schizoaffective disorder, schizophreniform disorder, major depressive disorder or bipolar disorder type I and II (currently in a depressive episode)
Conditions
Brief summary
Change in symptom severity total score from baseline (visit 2) to four-weeks (MDD)/six-weeks (SZ/BD) (visit 4). For SZ, this is measured using the Positive And Negative Syndrome Scale. For MDD and BD, Montgomery Asberg Depression Rating Scale is applied.
Detailed description
The secondary endpoints are already described in the secondary objectives
Interventions
DRUG-
DRUGsolution
DRUGESKETAMINE
DRUGBUPROPION
DRUGQUETIAPINE
DRUGVALPROIC ACID
DRUGVENLAFAXINE
DRUGLAMOTRIGINE
DRUGKETAMINE
DRUGSERTRALINE
DRUGDULOXETINE
DRUGCLOZAPINE
DRUGESCITALOPRAM
DRUGLITHIUM
Sponsors
University Medical Center Utrecht
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in symptom severity total score from baseline (visit 2) to four-weeks (MDD)/six-weeks (SZ/BD) (visit 4). For SZ, this is measured using the Positive And Negative Syndrome Scale. For MDD and BD, Montgomery Asberg Depression Rating Scale is applied. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints are already described in the secondary objectives | — |
Countries
Austria, Germany, Italy, Spain
Outcome results
None listed